Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities

PRINCETON, N.J., July 31, 2012 /PRNewswire/ -- Neura Therapeutik, LLC, a privately held specialty pharmaceutical company, announced today the formation of two strategic business units to capitalize on current and future opportunities in the analgesic market. The formation of Neura Group, LLC and Neura Labs, LLC structures the company to efficiently pursue commercial services, in-licensing, and joint venture opportunities in the analgesic marketplace.

Established by former King and Pfizer executives in 2010, Neura Therapeutik brings expertise in commercialization and development of analgesics, primarily in the NSAID and opioid classes of the pain market. Management's past experience includes directing pain franchise build outs and launching some of the largest US analgesic brands including Duragesic® patch and Vicodin ES® tablets. The formation of the business units allows Neura the ability to fully leverage its expertise in the analgesic market and build strong working alliances with strategic operational partners.

Through in-licensing and joint venture arrangements, the Neura Labs business unit will focus on establishing a portfolio of analgesic products with unique characteristics that fulfill unmet market needs, reside in the opioid and more specifically the tamper-resistant segment, or that have a high therapeutic index, or other unique pharmacokinetic or functional characteristics.

The Neura Group business unit provides companies interested in entering the analgesic market with a highly experienced turn-key commercial infrastructure and leadership team capable of rapidly establishing a total US operational presence. Neura Group offers best-in-class functional area expertise in CMC, regulatory and manufacturing scale-up to sales, marketing, launch readiness and lifecycle management.

"There are many nuances associated with analgesic commercialization. A commercial team with experience navigating the US analgesic marketplace is critical for the success of any product seeking to enter this market," said John La Lota, CEO of Neura Therapeutik. "Neura Therapeutik's two strategic business units provide an efficient solution to companies requiring an analgesic experienced commercial team whether they wish to retain the asset and leverage our commercial expertise, or if they seek an experienced company as a licensing partner."

Duragesic® is a registered trademark of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Vicodin ES® is a registered trademark of Abbott Laboratories.

Contact:

Neura Therapeutik, LLC
Greg Gironda: [email protected] 
Visit: www.neuratherapeutik.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com

SOURCE Neura Therapeutik, LLC

 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.